{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:44:54Z","timestamp":1792226694220,"version":"4.4.0"},"reference-count":194,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,8,10]]},"abstract":"<jats:sec><jats:title\/><jats:p>Rheumatoid arthritis (RA) is an autoimmune inflammatory arthritis. Inflammation, however, can spread beyond the joints to involve other organs. During the past few years, it has been well recognized that RA associates with increased risk for cardiovascular (CV) disease (CVD) compared with the general population. This seems to be due not only to the increased occurrence in RA of classical CVD risk factors and comorbidities like smoking, obesity, hypertension, diabetes, metabolic syndrome, and others but also to the inflammatory burden that RA itself carries. This is not unexpected given the strong links between inflammation and atherosclerosis and CVD. It has been shown that inflammatory cytokines which are present in abundance in RA play a significant role in every step of plaque formation and rupture. Most of the therapeutic regimes used in RA treatment seem to offer significant benefits to that end. However, more studies are needed to clarify the effect of these drugs on various parameters, including the lipid profile. Of note, although pharmacological intervention significantly helps reduce the inflammatory burden and therefore the CVD risk, control of the so-called classical risk factors is equally important. Herein, we review the current evidence for the underlying pathogenic mechanisms linking inflammation with CVD in the context of RA and reflect on the possible impact of treatments used in RA.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570161117666190619143842","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T11:37:57Z","timestamp":1561981077000},"page":"431-446","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":true,"given":"George E.","family":"Fragoulis","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-2176","authenticated-orcid":true,"given":"Ismini","family":"Panayotidis","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Medical School, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":true,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, King\u2019s College London, London, UK and Department of Rheumatology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","volume":"2","author":"Urman A.","year":"2018","unstructured":"Urman A.; Taklalsingh N.; Sorrento C.; McFarlane I.M.; Inflammation beyond the Joints: rheumatoid arthritis and cardiovascular disease. Scifed J Cardiol 2018,2(3)","journal-title":"Scifed J Cardiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"Avina-Zubieta J.A.","year":"2012","unstructured":"Avina-Zubieta J.A.; Thomas J.; Sadatsafavi M.; Lehman A.J.; Lacaille D.; Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012,71(9),1524-1529","journal-title":"Ann Rheum Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"Solomon D.H.","year":"2003","unstructured":"Solomon D.H.; Karlson E.W.; Rimm E.B.; Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003,107(9),1303-1307","journal-title":"Circulation"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/art.10705","volume":"48","author":"Gabriel S.E.","year":"2003","unstructured":"Gabriel S.E.; Crowson C.S.; Kremers H.M.; Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003,48(1),54-58","journal-title":"Arthritis Rheum"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1002\/art.22979","volume":"56","author":"Gonzalez A.","year":"2007","unstructured":"Gonzalez A.; Maradit Kremers H.; Crowson C.S.; The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007,56(11),3583-3587","journal-title":"Arthritis Rheum"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/annrheumdis-2018-214618","volume":"78","author":"Poppelaars P.B.M.","year":"2019","unstructured":"Poppelaars P.B.M.; van Tuyl L.H.D.; Boers M.; Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis 2019,78(5),586-589","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3899\/jrheum.161154","volume":"44","author":"Myasoedova E.","year":"2017","unstructured":"Myasoedova E.; Gabriel S.E.; Matteson E.L.; Davis J.M.; Therneau T.M.; Crowson C.S.; Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? J Rheumatol 2017,44(6),732-739","journal-title":"J Rheumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2018-214075","volume":"78","author":"Burggraaf B.","year":"2019","unstructured":"Burggraaf B.; van Breukelen-van der Stoep D.F.; de Vries M.A.; Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2019,78(3),335-341","journal-title":"Ann Rheum Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"Ridker P.M.","year":"2000","unstructured":"Ridker P.M.; Hennekens C.H.; Buring J.E.; Rifai N.; C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000,342(12),836-843","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"Libby P.","year":"2012","unstructured":"Libby P.; Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012,32(9),2045-2051","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"McInnes I.B.","year":"2007","unstructured":"McInnes I.B.; Schett G.; Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007,7(6),429-442","journal-title":"Nat Rev Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","volume":"35","author":"Taleb S.","year":"2015","unstructured":"Taleb S.; Tedgui A.; Mallat Z.; IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol 2015,35(2),258-264","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","volume":"108","author":"Sattar N.","year":"2003","unstructured":"Sattar N.; McCarey D.W.; Capell H.; McInnes I.B.; Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003,108(24),2957-2963","journal-title":"Circulation"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","volume":"11","author":"Skeoch S.","year":"2015","unstructured":"Skeoch S.; Bruce I.N.; Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015,11(7),390-400","journal-title":"Nat Rev Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1161\/01.CIR.99.24.3092","volume":"99","author":"Ito A.","year":"1999","unstructured":"Ito A.; Tsao P.S.; Adimoolam S.; Kimoto M.; Ogawa T.; Cooke J.P.; Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999,99(24),3092-3095","journal-title":"Circulation"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(96)09424-X","volume":"349","author":"Vallance P.","year":"1997","unstructured":"Vallance P.; Collier J.; Bhagat K.; Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997,349(9062),1391-1392","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1161\/01.ATV.0000065195.22904.FA","volume":"23","author":"Chia S.","year":"2003","unstructured":"Chia S.; Qadan M.; Newton R.; Ludlam C.A.; Fox K.A.; Newby D.E.; Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003,23(4),695-701","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clim.2011.07.003","volume":"141","author":"Zhu F.","year":"2011","unstructured":"Zhu F.; Wang Q.; Guo C.; IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 2011,141(2),152-160","journal-title":"Clin Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/1756-185X.12999","volume":"20","author":"Mahmoudi M.","year":"2017","unstructured":"Mahmoudi M.; Aslani S.; Fadaei R.; Jamshidi A.R.; New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int J Rheum Dis 2017,20(3),287-297","journal-title":"Int J Rheum Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1194\/jlr.M800484-JLR200","volume":"50","author":"Lei L.","year":"2009","unstructured":"Lei L.; Xiong Y.; Chen J.; TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res 2009,50(6),1057-1067","journal-title":"J Lipid Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.4049\/jimmunol.180.6.4316","volume":"180","author":"Singh S.K.","year":"2008","unstructured":"Singh S.K.; Suresh M.V.; Prayther D.C.; Moorman J.P.; Rusi\u00f1ol A.E.; Agrawal A.; C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 2008,180(6),4316-4322","journal-title":"J Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/ATVBAHA.107.159467","volume":"28","author":"Wang X.","year":"2008","unstructured":"Wang X.; Liao D.; Bharadwaj U.; Li M.; Yao Q.; Chen C.; C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2008,28(3),519-526","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"Tall A.R.","year":"2015","unstructured":"Tall A.R.; Yvan-Charvet L.; Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015,15(2),104-116","journal-title":"Nat Rev Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/ATVBAHA.108.179739","volume":"30","author":"Finn A.V.","year":"2010","unstructured":"Finn A.V.; Nakano M.; Narula J.; Kolodgie F.D.; Virmani R.; Concept of vulnerable\/unstable plaque. Arterioscler Thromb Vasc Biol 2010,30(7),1282-1292","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1194\/jlr.M700535-JLR200","volume":"49","author":"Singh U.","year":"2008","unstructured":"Singh U.; Dasu M.R.; Yancey P.G.; Afify A.; Devaraj S.; Jialal I.; Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008,49(5),1015-1023","journal-title":"J Lipid Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/art.39198","volume":"67","author":"Mackey R.H.","year":"2015","unstructured":"Mackey R.H.; Kuller L.H.; Deane K.D.; Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women\u2019s health initiative. Arthritis Rheumatol 2015,67(9),2311-2322","journal-title":"Arthritis Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.25009","volume":"61","author":"Rho Y.H.","year":"2009","unstructured":"Rho Y.H.; Chung C.P.; Oeser A.; Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009,61(11),1580-1585","journal-title":"Arthritis Rheum"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"R634","DOI":"10.1186\/ar1717","volume":"7","author":"Dessein P.H.","year":"2005","unstructured":"Dessein P.H.; Joffe B.I.; Singh S.; Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005,7(3),R634-R643","journal-title":"Arthritis Res Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1172\/JCI115950","volume":"90","author":"Koch A.E.","year":"1992","unstructured":"Koch A.E.; Kunkel S.L.; Harlow L.A.; Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992,90(3),772-779","journal-title":"J Clin Invest"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2009\/510104","volume":"26","author":"Navarro-Hern\u00e1ndez R.E.","year":"2009","unstructured":"Navarro-Hern\u00e1ndez R.E.; Oregon-Romero E.; V\u00e1zquez-Del Mercado M.; Rangel-Villalobos H.; Palafox-S\u00e1nchez C.A.; Mu\u00f1oz-Valle J.F.; Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis Markers 2009,26(3),119-126","journal-title":"Dis Markers"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1002\/art.30542","volume":"63","author":"Giles J.T.","year":"2011","unstructured":"Giles J.T.; Post W.S.; Blumenthal R.S.; Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011,63(11),3216-3225","journal-title":"Arthritis Rheum"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1002\/art.11327","volume":"48","author":"Nagata-Sakurai M.","year":"2003","unstructured":"Nagata-Sakurai M.; Inaba M.; Goto H.; Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 2003,48(11),3061-3067","journal-title":"Arthritis Rheum"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","volume":"73","author":"Karpouzas G.A.","year":"2014","unstructured":"Karpouzas G.A.; Malpeso J.; Choi T.Y.; Li D.; Munoz S.; Budoff M.J.; Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014,73(10),1797-1804","journal-title":"Ann Rheum Dis"},{"key":"ref=34","first-page":"937","volume":"34","author":"Aubry M.C.","year":"2007","unstructured":"Aubry M.C.; Maradit-Kremers H.; Reinalda M.S.; Crowson C.S.; Edwards W.D.; Gabriel S.E.; Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007,34(5),937-942","journal-title":"J Rheumatol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3899\/jrheum.120621","volume":"40","author":"Semb A.G.","year":"2013","unstructured":"Semb A.G.; Rollefstad S.; Provan S.A.; Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013,40(4),359-368","journal-title":"J Rheumatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.semarthrit.2010.06.006","volume":"40","author":"van Sijl A.M.","year":"2011","unstructured":"van Sijl A.M.; Peters M.J.; Knol D.K.; Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011,40(5),389-397","journal-title":"Semin Arthritis Rheum"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"R116","DOI":"10.1186\/ar2323","volume":"9","author":"Hannawi S.","year":"2007","unstructured":"Hannawi S.; Haluska B.; Marwick T.H.; Thomas R.; Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007,9(6),R116","journal-title":"Arthritis Res Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/ar3116","volume":"12","author":"S\u00f6dergren A.","year":"2010","unstructured":"S\u00f6dergren A.; Karp K.; Boman K.; Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010,12(4),R158","journal-title":"Arthritis Res Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2018.03.004","volume":"271","author":"Lo Gullo A.","year":"2018","unstructured":"Lo Gullo A.; Rodr\u00edguez-Carrio J.; Aragona C.O.; Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation. Atherosclerosis 2018,271,214-222","journal-title":"Atherosclerosis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/art.21204","volume":"52","author":"Goodson N.J.","year":"2005","unstructured":"Goodson N.J.; Symmons D.P.; Scott D.G.; Bunn D.; Lunt M.; Silman A.J.; Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005,52(8),2293-2299","journal-title":"Arthritis Rheum"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar3442","volume":"13","author":"Innala L.","year":"2011","unstructured":"Innala L.; M\u00f6ller B.; Ljung L.; Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011,13(4),R131","journal-title":"Arthritis Res Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/art.39267","volume":"67","author":"Mantel \u00c4.","year":"2015","unstructured":"Mantel \u00c4.; Holmqvist M.; Nyberg F.; Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol 2015,67(11),2845-2854","journal-title":"Arthritis Rheumatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","volume":"74","author":"Arts E.E.","year":"2015","unstructured":"Arts E.E.; Fransen J.; den Broeder A.A.; Popa C.D.; van Riel P.L.; The effect of disease duration and disease activity on the risk of cardio-vascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015,74(6),998-1003","journal-title":"Ann Rheum Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","volume":"73","author":"Zhang J.","year":"2014","unstructured":"Zhang J.; Chen L.; Delzell E.; The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2014,73(7),1301-1308","journal-title":"Ann Rheum Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"Solomon D.H.","year":"2015","unstructured":"Solomon D.H.; Reed G.W.; Kremer J.M.; Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015,67(6),1449-1455","journal-title":"Arthritis Rheumatol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","volume":"75","author":"Myasoedova E.","year":"2016","unstructured":"Myasoedova E.; Chandran A.; Ilhan B.; The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2016,75(3),560-565","journal-title":"Ann Rheum Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"Crowson C.S.","year":"2018","unstructured":"Crowson C.S.; Rollefstad S.; Ikdahl E.; Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018,77(1),48-54","journal-title":"Ann Rheum Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/art.10419","volume":"46","author":"Goodson N.J.","year":"2002","unstructured":"Goodson N.J.; Wiles N.J.; Lunt M.; Barrett E.M.; Silman A.J.; Symmons D.P.; Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002,46(8),2010-2019","journal-title":"Arthritis Rheum"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1136\/ard.2009.110536","volume":"69","author":"Tomasson G.","year":"2010","unstructured":"Tomasson G.; Aspelund T.; Jonsson T.; Valdimarsson H.; Felson D.T.; Gudnason V.; Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010,69(9),1649-1654","journal-title":"Ann Rheum Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/art.39195","volume":"67","author":"Solomon D.H.","year":"2015","unstructured":"Solomon D.H.; Greenberg J.; Curtis J.R.; Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol 2015,67(8),1995-2003","journal-title":"Arthritis Rheumatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/art.39302","volume":"67","author":"Montes A.","year":"2015","unstructured":"Montes A.; Corrales A.; Calaza M.; Brief report: lack of replication of an association between anti-citrullinated fibrinogen and subclinical atherosclerosis in patients with rheumatoid arthritis. Arthritis Rheumatol 2015,67(11),2861-2865","journal-title":"Arthritis Rheumatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/art.37961","volume":"65","author":"Sokolove J.","year":"2013","unstructured":"Sokolove J.; Brennan M.J.; Sharpe O.; Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013,65(7),1719-1724","journal-title":"Arthritis Rheum"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2013.02.009","volume":"228","author":"Cambridge G.","year":"2013","unstructured":"Cambridge G.; Acharya J.; Cooper J.A.; Edwards J.C.; Humphries S.E.; Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013,228(1),243-246","journal-title":"Atherosclerosis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s13075-014-0483-3","volume":"16","author":"Humphreys J.H.","year":"2014","unstructured":"Humphreys J.H.; van Nies J.A.; Chipping J.; Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014,16(6),483","journal-title":"Arthritis Res Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/art.24390","volume":"61","author":"L\u00f3pez-Longo F.J.","year":"2009","unstructured":"L\u00f3pez-Longo F.J.; Oliver-Mi\u00f1arro D.; de la Torre I.; Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009,61(4),419-424","journal-title":"Arthritis Rheum"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117952","volume":"10","author":"Baghdadi L.R.","year":"2015","unstructured":"Baghdadi L.R.; Woodman R.J.; Shanahan E.M.; Mangoni A.A.; The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015,10(2)","journal-title":"PLoS One"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","volume":"78","author":"Boyer J.F.","year":"2011","unstructured":"Boyer J.F.; Gourraud P.A.; Cantagrel A.; Davignon J.L.; Constantin A.; Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011,78(2),179-183","journal-title":"Joint Bone Spine"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"Naranjo A.","year":"2008","unstructured":"Naranjo A.; Sokka T.; Descalzo M.A.; Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008,10(2),R30","journal-title":"Arthritis Res Ther"},{"key":"ref=59","first-page":"115","volume":"33","author":"Jiang P.","year":"2015","unstructured":"Jiang P.; Li H.; Li X.; Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 2015,33(1),115-121","journal-title":"Clin Exp Rheumatol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/ard.2009.125476","volume":"69","author":"Solomon D.H.","year":"2010","unstructured":"Solomon D.H.; Love T.J.; Canning C.; Schneeweiss S.; Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and pso-riasis. Ann Rheum Dis 2010,69(12),2114-2117","journal-title":"Ann Rheum Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/BOR.0b013e32835fd7f8","volume":"25","author":"Barbhaiya M.","year":"2013","unstructured":"Barbhaiya M.; Solomon D.H.; Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013,25(3),317-324","journal-title":"Curr Opin Rheumatol"},{"key":"ref=62","first-page":"1403","volume":"30","author":"Dessein P.H.","year":"2003","unstructured":"Dessein P.H.; Joffe B.I.; Stanwix A.E.; Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003,30(7),1403-1405","journal-title":"J Rheumatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.38986","volume":"67","author":"Giles J.T.","year":"2015","unstructured":"Giles J.T.; Danielides S.; Szklo M.; Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol 2015,67(3),626-636","journal-title":"Arthritis Rheumatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/art.23600","volume":"58","author":"Chung C.P.","year":"2008","unstructured":"Chung C.P.; Oeser A.; Solus J.F.; Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008,58(7),2105-2112","journal-title":"Arthritis Rheum"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3132\/dvdr.2007.031","volume":"4","author":"La Montagna G.","year":"2007","unstructured":"La Montagna G.; Cacciapuoti F.; Buono R.; Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007,4(2),130-135","journal-title":"Diab Vasc Dis Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2011.599073","volume":"41","author":"S\u00f6derlin M.K.","year":"2012","unstructured":"S\u00f6derlin M.K.; Petersson I.F.; Geborek P.; The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012,41(1),1-9","journal-title":"Scand J Rheumatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/1756-185X.12307","volume":"17","author":"Lee Y.H.","year":"2014","unstructured":"Lee Y.H.; Bae S.C.; Song G.G.; Gene-environmental interaction between smoking and shared epitope on the development of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: a meta-analysis. Int J Rheum Dis 2014,17(5),528-535","journal-title":"Int J Rheum Dis"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.semarthrit.2011.07.004","volume":"41","author":"Chung C.P.","year":"2012","unstructured":"Chung C.P.; Giles J.T.; Petri M.; Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012,41(4),535-544","journal-title":"Semin Arthritis Rheum"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.atherosclerosis.2007.01.004","volume":"196","author":"Chung C.P.","year":"2008","unstructured":"Chung C.P.; Oeser A.; Solus J.F.; Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008,196(2),756-763","journal-title":"Atherosclerosis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","volume":"47","author":"Panoulas V.F.","year":"2008","unstructured":"Panoulas V.F.; Metsios G.S.; Pace A.V.; Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008,47(9),1286-1298","journal-title":"Rheumatology (Oxford)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar4324","volume":"15","author":"Protogerou A.D.","year":"2013","unstructured":"Protogerou A.D.; Panagiotakos D.B.; Zampeli E.; Arterial hypertension assessed \u201cout-of-office\u201d in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated \u201cwhite coat\u201d phenomenon. Arthritis Res Ther 2013,15(5),R142","journal-title":"Arthritis Res Ther"},{"key":"ref=72","first-page":"435","volume":"32","author":"Dessein P.H.","year":"2005","unstructured":"Dessein P.H.; Joffe B.I.; Veller M.G.; Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005,32(3),435-442","journal-title":"J Rheumatol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/acr.21693","volume":"64","author":"Curtis J.R.","year":"2012","unstructured":"Curtis J.R.; John A.; Baser O.; Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012,64(9),1282-1291","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/ard.2009.115717","volume":"69","author":"Toms T.E.","year":"2010","unstructured":"Toms T.E.; Panoulas V.F.; Douglas K.M.; Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010,69(4),683-688","journal-title":"Ann Rheum Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"Myasoedova E.","year":"2011","unstructured":"Myasoedova E.; Crowson C.S.; Kremers H.M.; Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011,70(3),482-487","journal-title":"Ann Rheum Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/PL00011174","volume":"19","author":"Lee Y.H.","year":"2000","unstructured":"Lee Y.H.; Choi S.J.; Ji J.D.; Seo H.S.; Song G.G.; Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000,19(4),324-325","journal-title":"Clin Rheumatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/art.34363","volume":"64","author":"Watanabe J.","year":"2012","unstructured":"Watanabe J.; Charles-Schoeman C.; Miao Y.; Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012,64(6),1828-1837","journal-title":"Arthritis Rheum"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/ard.2004.022061","volume":"63","author":"McInnes I.B.","year":"2004","unstructured":"McInnes I.B.; McCarey D.W.; Sattar N.; Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis 2004,63(12),1535-1537","journal-title":"Ann Rheum Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fmed.2018.00024","volume":"5","author":"Soulaidopoulos S.","year":"2018","unstructured":"Soulaidopoulos S.; Nikiphorou E.; Dimitroulas T.; Kitas G.D.; The role of statins in disease modification and cardiovascular risk in rheuma-toid arthritis. Front Med (Lausanne) 2018,5,24","journal-title":"Front Med (Lausanne)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"Agca R.","year":"2017","unstructured":"Agca R.; Heslinga S.C.; Rollefstad S.; EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 2017,76(1),17-28","journal-title":"Ann Rheum Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"McCarey D.W.","year":"2004","unstructured":"McCarey D.W.; McInnes I.B.; Madhok R.; Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004,363(9426),2015-2021","journal-title":"Lancet"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.40892","volume":"71","author":"Kitas G.D.","year":"2019","unstructured":"Kitas G.D.; Nightingale P.; Armitage J.; Sattar N.; Belch J.J.F.; Symmons D.P.M.; Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial. Arthritis Rheumatol 2019,71(9),1437-1449","journal-title":"Arthritis Rheumatol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Baigent C.","year":"2010","unstructured":"Baigent C.; Blackwell L.; Emberson J.; Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Cholesterol Treatment Trialists\u2019 (CTT) Collaboration2010,376(9753),1670-1681","journal-title":"Lancet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.110318","volume":"39","author":"Sheng X.","year":"2012","unstructured":"Sheng X.; Murphy M.J.; Macdonald T.M.; Wei L.; Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012,39(1),32-40","journal-title":"J Rheumatol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/art.39114","volume":"67","author":"Rollefstad S.","year":"2015","unstructured":"Rollefstad S.; Ikdahl E.; Hisdal J.; Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Arthritis Rheumatol 2015,67(7),1718-1728","journal-title":"Arthritis Rheumatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/keq295","volume":"50","author":"Semb A.G.","year":"2011","unstructured":"Semb A.G.; Holme I.; Kvien T.K.; Pedersen T.R.; Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011,50(2),324-329","journal-title":"Rheumatology (Oxford)"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2012-202254","volume":"72","author":"de Hair M.J.","year":"2013","unstructured":"de Hair M.J.; Landew\u00e9 R.B.; van de Sande M.G.; Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013,72(10),1654-1658","journal-title":"Ann Rheum Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2014-205459","volume":"73","author":"Lu B.","year":"2014","unstructured":"Lu B.; Hiraki L.T.; Sparks J.A.; Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 2014,73(11),1914-1922","journal-title":"Ann Rheum Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.21710","volume":"65","author":"Ajeganova S.","year":"2013","unstructured":"Ajeganova S.; Andersson M.L.; Hafstr\u00f6m I.; Group B.S.; Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow up from disease onset. Arthritis Care Res (Hoboken) 2013,65(1),78-87","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1136\/annrheumdis-2014-205741","volume":"73","author":"Finckh A.","year":"2014","unstructured":"Finckh A.; Turesson C.; The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis 2014,73(11),1911-1913","journal-title":"Ann Rheum Dis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/rheumatology\/key066","volume":"57","author":"Nikiphorou E.","year":"2018","unstructured":"Nikiphorou E.; Norton S.; Young A.; The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the early rheumatoid arthritis study\/early rheumatoid arthritis network UK prospective cohorts. Rheumatology (Oxford) 2018,57(7),1194-1202","journal-title":"Rheumatology (Oxford)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1002\/art.23033","volume":"56","author":"Westhoff G.","year":"2007","unstructured":"Westhoff G.; Rau R.; Zink A.; Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007,56(11),3575-3582","journal-title":"Arthritis Rheum"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000458","volume":"3","author":"Levitsky A.","year":"2017","unstructured":"Levitsky A.; Brismar K.; Hafstr\u00f6m I.; Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open 2017,3(2)","journal-title":"RMD Open"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1759720X18783894","volume":"10","author":"Nikiphorou E.","year":"2018","unstructured":"Nikiphorou E.; Fragoulis G.E.; Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis 2018,10(8),157-167","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3899\/jrheum.101036","volume":"38","author":"Rajbhandary R.","year":"2011","unstructured":"Rajbhandary R.; Khezri A.; Panush R.S.; Rheumatoid cachexia: what is it and why is it important? J Rheumatol 2011,38(3),406-408","journal-title":"J Rheumatol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0167-5273(02)00237-1","volume":"85","author":"Walsmith J.","year":"2002","unstructured":"Walsmith J.; Roubenoff R.; Cachexia in rheumatoid arthritis. Int J Cardiol 2002,85(1),89-99","journal-title":"Int J Cardiol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/art.27629","volume":"62","author":"Giles J.T.","year":"2010","unstructured":"Giles J.T.; Allison M.; Blumenthal R.S.; Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010,62(11),3173-3182","journal-title":"Arthritis Rheum"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/archinte.165.14.1624","volume":"165","author":"Escalante A.","year":"2005","unstructured":"Escalante A.; Haas R.W.; del Rinc\u00f3n I.; Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005,165(14),1624-1629","journal-title":"Arch Intern Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1002\/art.20612","volume":"50","author":"Kremers H.M.","year":"2004","unstructured":"Kremers H.M.; Nicola P.J.; Crowson C.S.; Ballman K.V.; Gabriel S.E.; Prognostic importance of low body mass index in relation to cardi-ovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004,50(11),3450-3457","journal-title":"Arthritis Rheum"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2014.00576","volume":"5","author":"Gremese E.","year":"2014","unstructured":"Gremese E.; Tolusso B.; Gigante M.R.; Ferraccioli G.; Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 2014,5,576","journal-title":"Front Immunol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/08916934.2016.1230847","volume":"49","author":"Cao H.","year":"2016","unstructured":"Cao H.; Lin J.; Chen W.; Xu G.; Sun C.; Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: A meta-analysis and systematic review. Autoimmunity 2016,49(8),547-553","journal-title":"Autoimmunity"},{"key":"ref=102","first-page":"222","volume":"27","author":"Gonzalez-Gay M.A.","year":"2009","unstructured":"Gonzalez-Gay M.A.; Garcia-Unzueta M.T.; Berja A.; Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009,27(2),222-228","journal-title":"Clin Exp Rheumatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/ard.2005.040857","volume":"65","author":"H\u00e4rle P.","year":"2006","unstructured":"H\u00e4rle P.; Sarzi-Puttini P.; Cutolo M.; Straub R.H.; No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006,65(7),970-971","journal-title":"Ann Rheum Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3899\/jrheum.080626","volume":"36","author":"Popa C.","year":"2009","unstructured":"Popa C.; Netea M.G.; de Graaf J.; Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009,36(4),724-730","journal-title":"J Rheumatol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar2844","volume":"11","author":"Choi H.M.","year":"2009","unstructured":"Choi H.M.; Lee Y.A.; Lee S.H.; Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009,11(6),R161","journal-title":"Arthritis Res Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.27616","volume":"62","author":"Frommer K.W.","year":"2010","unstructured":"Frommer K.W.; Zimmermann B.; Meier F.M.; Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010,62(10),2886-2899","journal-title":"Arthritis Rheum"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-018-1526-y","volume":"20","author":"Qian J.","year":"2018","unstructured":"Qian J.; Xu L.; Sun X.; Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2018,20(1),26","journal-title":"Arthritis Res Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1136\/ard.2011.150813","volume":"70","author":"Giles J.T.","year":"2011","unstructured":"Giles J.T.; van der Heijde D.M.; Bathon J.M.; Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011,70(9),1562-1568","journal-title":"Ann Rheum Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/1756-185X.13038","volume":"21","author":"Lee Y.H.","year":"2018","unstructured":"Lee Y.H.; Bae S.C.; Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Int J Rheum Dis 2018,21(3),664-672","journal-title":"Int J Rheum Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13075-017-1472-0","volume":"19","author":"Sato H.","year":"2017","unstructured":"Sato H.; Muraoka S.; Kusunoki N.; Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 2017,19(1),263","journal-title":"Arthritis Res Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/ard.2005.046540","volume":"65","author":"Otero M.","year":"2006","unstructured":"Otero M.; Lago R.; Gomez R.; Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006,65(9),1198-1201","journal-title":"Ann Rheum Dis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/art.24626","volume":"60","author":"Rho Y.H.","year":"2009","unstructured":"Rho Y.H.; Solus J.; Sokka T.; Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009,60(7),1906-1914","journal-title":"Arthritis Rheum"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2017-212392","volume":"77","author":"Weijers J.M.","year":"2018","unstructured":"Weijers J.M.; Rongen-van Dartel S.A.A.; Hoevenaars D.M.G.M.F.; Rubens M.; Hulscher M.E.J.L.; van Riel P.L.C.M.; Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care. Ann Rheum Dis 2018,77(4),480-483","journal-title":"Ann Rheum Dis"},{"key":"ref=114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103495","volume":"9","author":"Sglunda O.","year":"2014","unstructured":"Sglunda O.; Mann H.; Hulejov\u00e1 H.; Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort. PLoS One 2014,9(7)","journal-title":"PLoS One"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.22482","volume":"57","author":"Gonzalez-Gay M.A.","year":"2007","unstructured":"Gonzalez-Gay M.A.; Gonzalez-Juanatey C.; Lopez-Diaz M.J.; HLA-DRB1 and persistent chronic inflammation contribute to car-diovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007,57(1),125-132","journal-title":"Arthritis Rheum"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9343(03)00133-5","volume":"114","author":"Gonzalez-Juanatey C.","year":"2003","unstructured":"Gonzalez-Juanatey C.; Testa A.; Garcia-Castelo A.; HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003,114(8),647-652","journal-title":"Am J Med"},{"key":"ref=117","first-page":"964","volume":"27","author":"Palomino-Morales R.","year":"2009","unstructured":"Palomino-Morales R.; Gonzalez-Juanatey C.; Vazquez-Rodriguez T.R.; Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009,27(6),964-970","journal-title":"Clin Exp Rheumatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1186\/ar2989","volume":"12","author":"Palomino-Morales R.","year":"2010","unstructured":"Palomino-Morales R.; Gonzalez-Juanatey C.; Vazquez-Rodriguez T.R.; A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010,12(2),R71","journal-title":"Arthritis Res Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2008.08.036","volume":"204","author":"Panoulas V.F.","year":"2009","unstructured":"Panoulas V.F.; Stavropoulos-Kalinoglou A.; Metsios G.S.; Association of interleukin-6 (IL-6)-174G\/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009,204(1),178-183","journal-title":"Atherosclerosis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/rheumatology\/ken443","volume":"48","author":"Panoulas V.F.","year":"2009","unstructured":"Panoulas V.F.; Douglas K.M.; Smith J.P.; Transforming growth factor-beta1 869T\/C, but not interleukin-6 -174G\/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2009,48(2),113-118","journal-title":"Rheumatology (Oxford)"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10623320802228708","volume":"15","author":"Panoulas V.F.","year":"2008","unstructured":"Panoulas V.F.; Douglas K.M.; Smith J.P.; Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 2008,15(4),203-212","journal-title":"Endothelium"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","volume":"73","author":"Lindhardsen J.","year":"2014","unstructured":"Lindhardsen J.; Gislason G.H.; Jacobsen S.; Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014,73(8),1515-1521","journal-title":"Ann Rheum Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"Roubille C.","year":"2015","unstructured":"Roubille C.; Richer V.; Starnino T.; The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015,74(3),480-489","journal-title":"Ann Rheum Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"Johnson A.G.","year":"1994","unstructured":"Johnson A.G.; Nguyen T.V.; Day R.O.; Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994,121(4),289-300","journal-title":"Ann Intern Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MNH.0000000000000473","volume":"28","author":"Sriperumbuduri S.","year":"2019","unstructured":"Sriperumbuduri S.; Hiremath S.; The case for cautious consumption: NSAIDs in chronic kidney disease. Curr Opin Nephrol Hypertens 2019,28(2),163-170","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/rheumatology\/kes353","volume":"52","author":"Avi\u00f1a-Zubieta J.A.","year":"2013","unstructured":"Avi\u00f1a-Zubieta J.A.; Abrahamowicz M.; De Vera M.A.; Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013,52(1),68-75","journal-title":"Rheumatology (Oxford)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.38210","volume":"66","author":"del Rinc\u00f3n I.","year":"2014","unstructured":"del Rinc\u00f3n I.; Battafarano D.F.; Restrepo J.F.; Erikson J.M.; Escalante A.; Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014,66(2),264-272","journal-title":"Arthritis Rheumatol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","volume":"6","author":"Tamez-P\u00e9rez H.E.","year":"2015","unstructured":"Tamez-P\u00e9rez H.E.; Quintanilla-Flores D.L.; Rodr\u00edguez-Guti\u00e9rrez R.; Gonz\u00e1lez-Gonz\u00e1lez J.G.; Tamez-Pe\u00f1a A.L.; Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes 2015,6(8),1073-1081","journal-title":"World J Diabetes"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1517\/14740338.2015.1027681","volume":"14","author":"Rasch L.A.","year":"2015","unstructured":"Rasch L.A.; Bultink I.E.; van Tuyl L.H.; Lems W.F.; Glucocorticoid safety for treating rheumatoid arthritis. Expert Opin Drug Saf 2015,14(6),839-844","journal-title":"Expert Opin Drug Saf"},{"key":"ref=130","first-page":"1024","volume":"17","author":"B\u0103l\u0103nescu A.R.","year":"2019","unstructured":"B\u0103l\u0103nescu A.R.; Bojinc\u0103 V.C.; Bojinc\u0103 M.; Donisan T.; B\u0103l\u0103nescu S.M.; Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med 2019,17(2),1024-1029","journal-title":"Exp Ther Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fcvm.2018.00177","volume":"5","author":"Bartoloni E.","year":"2018","unstructured":"Bartoloni E.; Alunno A.; Valentini V.; Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality? Front Cardiovasc Med 2018,5,177","journal-title":"Front Cardiovasc Med"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212557","volume":"7","author":"Mangoni A.A.","year":"2018","unstructured":"Mangoni A.A.; Tommasi S.; Zinellu A.; Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018,7","journal-title":"Drugs Context"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.39039","volume":"67","author":"Ronda N.","year":"2015","unstructured":"Ronda N.; Greco D.; Adorni M.P.; Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015,67(5),1155-1164","journal-title":"Arthritis Rheumatol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"Reiss A.B.","year":"2008","unstructured":"Reiss A.B.; Carsons S.E.; Anwar K.; Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum 2008,58(12),3675-3683","journal-title":"Arthritis Rheum"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39833","volume":"69","author":"Charles-Schoeman C.","year":"2017","unstructured":"Charles-Schoeman C.; Yin Lee Y.; Shahbazian A.; Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol 2017,69(1),46-57","journal-title":"Arthritis Rheumatol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.redox.2017.07.018","volume":"13","author":"Zimmerman M.C.","year":"2017","unstructured":"Zimmerman M.C.; Clemens D.L.; Duryee M.J.; Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging. Redox Biol 2017,13,588-593","journal-title":"Redox Biol"},{"key":"ref=137","first-page":"415","volume":"31","author":"Hjeltnes G.","year":"2013","unstructured":"Hjeltnes G.; Hollan I.; F\u00f8rre O.; Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-\u03b1-inhibitor. Clin Exp Rheumatol 2013,31(3),415-421","journal-title":"Clin Exp Rheumatol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10067-014-2769-x","volume":"35","author":"MacMullan P.A.","year":"2016","unstructured":"MacMullan P.A.; Madigan A.M.; Paul N.; Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2016,35(2),447-455","journal-title":"Clin Rheumatol"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/jrms.JRMS_869_17","volume":"23","author":"Karimifar M.","year":"2018","unstructured":"Karimifar M.; Sepehrifar M.S.; Moussavi H.; The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. J Res Med Sci 2018,23,105","journal-title":"J Res Med Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar2045","volume":"8","author":"van Halm V.P.","year":"2006","unstructured":"van Halm V.P.; Nurmohamed M.T.; Twisk J.W.; Dijkmans B.A.; Voskuyl A.E.; Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006,8(5),R151","journal-title":"Arthritis Res Ther"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/1756-185X.12986","volume":"20","author":"Tam H.W.","year":"2017","unstructured":"Tam H.W.; Yeo K.J.; Leong P.Y.; Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. Int J Rheum Dis 2017,20(3),363-370","journal-title":"Int J Rheum Dis"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3899\/jrheum.100564","volume":"38","author":"Serelis J.","year":"2011","unstructured":"Serelis J.; Panagiotakos D.B.; Mavrommati M.; Skopouli F.N.; Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study. J Rheumatol 2011,38(2),236-241","journal-title":"J Rheumatol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/art.22255","volume":"54","author":"Solomon D.H.","year":"2006","unstructured":"Solomon D.H.; Avorn J.; Katz J.N.; Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006,54(12),3790-3798","journal-title":"Arthritis Rheum"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.61.6.567","volume":"61","author":"Rozman B.","year":"2002","unstructured":"Rozman B.; Praprotnik S.; Logar D.; Leflunomide and hypertension. Ann Rheum Dis 2002,61(6),567-569","journal-title":"Ann Rheum Dis"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/acr.22341","volume":"66","author":"Kerr G.","year":"2014","unstructured":"Kerr G.; Aujero M.; Richards J.; Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014,66(11),1619-1626","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/acr.20393","volume":"63","author":"Morris S.J.","year":"2011","unstructured":"Morris S.J.; Wasko M.C.; Antohe J.L.; Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011,63(4),530-534","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"Rempenault C.","year":"2018","unstructured":"Rempenault C.; Combe B.; Barnetche T.; Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018,77(1),98-103","journal-title":"Ann Rheum Dis"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213157","volume":"78","author":"Li H.Z.","year":"2019","unstructured":"Li H.Z.; Xu X.H.; Lin N.; Lu H.D.; Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2019,78(3)","journal-title":"Ann Rheum Dis"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/ard.2006.063867","volume":"66","author":"Dixon W.G.","year":"2007","unstructured":"Dixon W.G.; Symmons D.P.; What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007,66(9),1132-1136","journal-title":"Ann Rheum Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"Low A.S.","year":"2017","unstructured":"Low A.S.; Symmons D.P.; Lunt M.; Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017,76(4),654-660","journal-title":"Ann Rheum Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40264-017-0628-9","volume":"41","author":"Nurmohamed M.","year":"2018","unstructured":"Nurmohamed M.; Choy E.; Lula S.; Kola B.; DeMasi R.; Accossato P.; The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf 2018,41(5),473-488","journal-title":"Drug Saf"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/annrheumdis-2012-201489","volume":"72","author":"Da\u00efen C.I.","year":"2013","unstructured":"Da\u00efen C.I.; Fesler P.; du Cailar G.; Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis 2013,72(6),881-887","journal-title":"Ann Rheum Dis"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/ard.2009.124180","volume":"69","author":"Klarenbeek N.B.","year":"2010","unstructured":"Klarenbeek N.B.; van der Kooij S.M.; Huizinga T.J.; Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010,69(7),1342-1345","journal-title":"Ann Rheum Dis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2012.02.002","volume":"42","author":"Dulai R.","year":"2012","unstructured":"Dulai R.; Perry M.; Twycross-Lewis R.; Morrissey D.; Atzeni F.; Greenwald S.; The effect of tumor necrosis factor-\u03b1 antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum 2012,42(1),1-8","journal-title":"Semin Arthritis Rheum"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/rheumatology\/ket454","volume":"53","author":"Tam L.S.","year":"2014","unstructured":"Tam L.S.; Kitas G.D.; Gonz\u00e1lez-Gay M.A.; Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014,53(6),1108-1119","journal-title":"Rheumatology (Oxford)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41598-017-05759-2","volume":"7","author":"Ursini F.","year":"2017","unstructured":"Ursini F.; Leporini C.; Bene F.; Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep 2017,7(1),5346","journal-title":"Sci Rep"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/art.38894","volume":"67","author":"Souto A.","year":"2015","unstructured":"Souto A.; Salgado E.; Maneiro J.R.; Mera A.; Carmona L.; G\u00f3mez-Reino J.J.; Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015,67(1),117-127","journal-title":"Arthritis Rheumatol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.2174\/0929867322666150209160701","volume":"22","author":"Heslinga S.C.","year":"2015","unstructured":"Heslinga S.C.; Van Sijl A.M.; De Boer K.; Van Halm V.P.; Nurmohamed M.T.; Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review. Curr Med Chem 2015,22(16),1892-1902","journal-title":"Curr Med Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1570161114666161013113457","volume":"15","author":"Kotani K.","year":"2017","unstructured":"Kotani K.; Miyamoto M.; Ando H.; The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis. Curr Vasc Pharmacol 2017,15(1),10-18","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/JIR.S156822","volume":"11","author":"Benucci M.","year":"2018","unstructured":"Benucci M.; Bandinelli F.; Damiani A.; Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis. J Inflamm Res 2018,11,247-252","journal-title":"J Inflamm Res"},{"key":"ref=161","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000888","volume":"94","author":"Ursini F.","year":"2015","unstructured":"Ursini F.; Russo E.; Letizia Hribal M.; Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 2015,94(21)","journal-title":"Medicine (Baltimore)"},{"key":"ref=162","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007393","volume":"7","author":"Kang E.H.","year":"2018","unstructured":"Kang E.H.; Jin Y.; Brill G.; Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 2018,7(3)","journal-title":"J Am Heart Assoc"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Jin Y.","year":"2018","unstructured":"Jin Y.; Kang E.H.; Brill G.; Desai R.J.; Kim S.C.; Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol 2018,45(9),1240-1248","journal-title":"J Rheumatol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"Zhang J.","year":"2016","unstructured":"Zhang J.; Xie F.; Yun H.; Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016,75(10),1813-1818","journal-title":"Ann Rheum Dis"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00296-018-4196-9","volume":"39","author":"Generali E.","year":"2019","unstructured":"Generali E.; Carrara G.; Kallikourdis M.; Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int 2019,39(2),239-243","journal-title":"Rheumatol Int"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"McInnes I.B.","year":"2015","unstructured":"McInnes I.B.; Thompson L.; Giles J.T.; Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015,74(4),694-702","journal-title":"Ann Rheum Dis"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3899\/jrheum.110340","volume":"38","author":"Kume K.","year":"2011","unstructured":"Kume K.; Amano K.; Yamada S.; Hatta K.; Ohta H.; Kuwaba N.; Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011,38(10),2169-2171","journal-title":"J Rheumatol"},{"key":"ref=168","first-page":"465","volume":"37","author":"Castaneda S.","year":"2019","unstructured":"Castaneda S.; Remuzgo-Martinez S.; Lopez-Mejias R.; Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol 2019,37(3),465-473","journal-title":"Clin Exp Rheumatol"},{"key":"ref=169","first-page":"293","volume":"37","author":"Fioravanti A.","year":"2019","unstructured":"Fioravanti A.; Tenti S.; Bacarelli M.R.; Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition. Clin Exp Rheumatol 2019,37(2),293-300","journal-title":"Clin Exp Rheumatol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1759720X18798462","volume":"10","author":"Jones G.","year":"2018","unstructured":"Jones G.; Panova E.; New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2018,10(10),195-199","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"Kim S.C.","year":"2018","unstructured":"Kim S.C.; Solomon D.H.; Rogers J.R.; No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum 2018,48(3),399-405","journal-title":"Semin Arthritis Rheum"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/acr.23737","volume":"71","author":"Xie F.","year":"2019","unstructured":"Xie F.; Yun H.; Levitan E.B.; Muntner P.; Curtis J.R.; Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res 2019,71(8),1004-1018","journal-title":"Arthritis Care Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"Singh S.","year":"2020","unstructured":"Singh S.; Fumery M.; Singh A.G.; Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2020,72(4),561-576","journal-title":"Arthritis Care Res"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"Charles-Schoeman C.","year":"2016","unstructured":"Charles-Schoeman C.; Wicker P.; Gonzalez-Gay M.A.; Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016,46(3),261-271","journal-title":"Semin Arthritis Rheum"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","volume":"37","author":"Kume K.","year":"2017","unstructured":"Kume K.; Amano K.; Yamada S.; Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int 2017,37(12),2079-2085","journal-title":"Rheumatol Int"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","volume":"490","author":"Wang Z.","year":"2017","unstructured":"Wang Z.; Wang S.; Wang Z.; Yun T.; Wang C.; Wang H.; Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. Biochem Biophys Res Commun 2017,490(2),194-201","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=177","first-page":"S35","volume":"26","author":"Sokka T.","year":"2008","unstructured":"Sokka T.; Abelson B.; Pincus T.; Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008,26(5)(Suppl. 51),S35-S61","journal-title":"Clin Exp Rheumatol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","volume":"37","author":"van den Hoek J.","year":"2017","unstructured":"van den Hoek J.; Boshuizen H.C.; Roorda L.D.; Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int 2017,37(4),487-493","journal-title":"Rheumatol Int"},{"key":"ref=179","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000737","volume":"4","author":"Ikdahl E.","year":"2018","unstructured":"Ikdahl E.; Rollefstad S.; Wibetoe G.; Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: ex-periences from the nationwide NOCAR project. RMD Open 2018,4(2)","journal-title":"RMD Open"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-017-0643-y","volume":"19","author":"Chodara A.M.","year":"2017","unstructured":"Chodara A.M.; Wattiaux A.; Bartels C.M.; Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches. Curr Rheumatol Rep 2017,19(4),16","journal-title":"Curr Rheumatol Rep"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/kew440","volume":"56","author":"Alemao E.","year":"2017","unstructured":"Alemao E.; Cawston H.; Bourhis F.; Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford) 2017,56(5),777-786","journal-title":"Rheumatology (Oxford)"},{"key":"ref=182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205506","volume":"13","author":"Navarini L.","year":"2018","unstructured":"Navarini L.; Margiotta D.P.E.; Caso F.; Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS One 2018,13(10)","journal-title":"PLoS One"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","volume":"56","author":"Crowson C.S.","year":"2017","unstructured":"Crowson C.S.; Gabriel S.E.; Semb A.G.; Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 2017,56(7),1102-1110","journal-title":"Rheumatology (Oxford)"},{"key":"ref=184","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000771","volume":"4","author":"Ljung L.","year":"2018","unstructured":"Ljung L.; Ueda P.; Liao K.P.; Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis in a ge-ographically distant national register-based cohort: an external validation. RMD Open 2018,4(2)","journal-title":"RMD Open"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3899\/jrheum.171008","volume":"46","author":"Wahlin B.","year":"2019","unstructured":"Wahlin B.; Innala L.; Magnusson S.; Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC\/AHA Risk Calculator. J Rheumatol 2019,46(2),130-137","journal-title":"J Rheumatol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/rheumatology\/kew497","volume":"56","author":"van den Oever I.A.M.","year":"2017","unstructured":"van den Oever I.A.M.; Heslinga M.; Griep E.N.; Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the implementation of cardiovascular risk management in rheumatoid arthritis project. Rheumatology (Oxford) 2017,56(9),1472-1478","journal-title":"Rheumatology (Oxford)"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/art.30239","volume":"63","author":"Bartels C.M.","year":"2011","unstructured":"Bartels C.M.; Kind A.J.; Everett C.; Mell M.; McBride P.; Smith M.; Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum 2011,63(5),1221-1230","journal-title":"Arthritis Rheum"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/acr.23094","volume":"69","author":"Jafri K.","year":"2017","unstructured":"Jafri K.; Bartels C.M.; Shin D.; Gelfand J.M.; Ogdie A.; Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 2017,69(1),51-57","journal-title":"Arthritis Care Res"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"k1036","DOI":"10.1136\/bmj.k1036","volume":"361","author":"England B.R.","year":"2018","unstructured":"England B.R.; Thiele G.M.; Anderson D.R.; Mikuls T.R.; Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018,361,k1036","journal-title":"BMJ"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/acr.22711","volume":"68","author":"Khoja S.S.","year":"2016","unstructured":"Khoja S.S.; Almeida G.J.; Chester Wasko M.; Terhorst L.; Piva S.R.; Association of light-intensity physical activity with lower cardiovascular disease risk burden in rheumatoid arthritis. Arthritis Care Res 2016,68(4),424-431","journal-title":"Arthritis Care Res"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/annrheumdis-2013-203291","volume":"73","author":"Metsios G.S.","year":"2014","unstructured":"Metsios G.S.; Stavropoulos-Kalinoglou A.; Veldhuijzen van Zanten J.J.; Individualized exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014,73(4),748-751","journal-title":"Ann Rheum Dis"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00296-018-4183-1","volume":"39","author":"Veldhuijzen van Zanten J.J.C.S.","year":"2019","unstructured":"Veldhuijzen van Zanten J.J.C.S.; Sandoo A.; Metsios G.S.; Stavropoulos-Kalinoglou A.; Ntoumanis N.; Kitas G.D.; Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: results from two controlled trials. Rheumatol Int 2019,39(2),219-225","journal-title":"Rheumatol Int"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1570161115666171116163816","volume":"17","author":"Dattilo G.","year":"2019","unstructured":"Dattilo G.; Borgia F.; Guarneri C.; Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol 2019,17(1),85-91","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/annrheumdis-2014-206617","volume":"74","author":"Kristensen S.L.","year":"2015","unstructured":"Kristensen S.L.; McInnes I.B.; Sattar N.; Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Ann Rheum Dis 2015,74(2),321-322","journal-title":"Ann Rheum Dis"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/172825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/172825\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/172825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:03:27Z","timestamp":1694988207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/172825\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":194,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,8,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190619143842","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}